P. E. Postmus (Amsterdam, The Netherlands), R. Huber (Munich, Germany)
Prognostic impact of FDG-PET in recurrence of surgically treated non-small cell lung cancer
A. Gröschel, D. Hellwig, T. Graeter, D. Ukena, H. J. Schäfers, C. M. Kirsch, G. W. Sybrecht (Homburg, Germany)
|   |
Management of bone metastases (BM): results of a large multinational, multidisciplinary survey
J. Guigay, J. Y. Bobin, J. L. Lagrnage, J. D. Laredo, M. Tubiana-Hulin, J. J. Body, the GEMO (Groupe Européen francophone d'étude des Métastases Osseuses) (Clamart, Lyon, Créteil, Paris, Saint-Cloud, France; Brussels, Belgium)
| |
Stenting in malignant superior vena caval obstruction: an eight year experience in a district general hospital
R. Santhanakrishnan, C. George, C. Prys-Pickard, P. Woodhead, F. Zaman (Burnley, United Kingdom)
| |
Age and stage at presentation in lung cancer
J. R. Ramsay, N. Turner, M. Muers (Leeds, United Kingdom)
| |
Delays in lung cancer management
H. Koyi, G. Hillerdal, E. Brandén (Stockholm, Sweden)
| |
Predictors of major serious manifestations in the terminal stage of lung cancer
K. Skaug, G. E. Eide, A. Gulsvik (Haugesund, Bergen, Norway)
| |
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
A. Rigas, N. Maouni, N. Trakas, P. Stylianou, E. Dimopoulou, A. Kotanidou, M. Chorti, P. Ziotopoulos, D. Orphanidou, F. Palamidas (Athens, Greece)
| |